Jonathan Afari, MD, of the University of California, San Diego, elaborates on the importance of identifying factors contributing to renal function improvement post-partial nephrectomy. Partial nephrectomy is considered a viable management strategy for patients with localized renal masses. A proportion of patients experience renal function improvement post-partial nephrectomy. ...
Localized Renal Cell Carcinoma
Advertisement
Latest News
Dr. Afari and colleagues sought to better understand factors leading to renal function improvement after partial nephrectomy.
For patients with primary RCC who are ineligible for surgical resection, SABR serves as a viable alternative.
FASTRACK II was the first trial of its kind to examine nonsurgical definitive therapy in patients with primary RCC.
While RLRN and TLRN procedures were found to have similar efficacy, TLRN also resulted in better surgical specimen integrity.
Dr. Grünwald describes the CheckMate 914 Part B analysis and investigating adjuvant nivo for patients with localized RCC.
After 57 months of follow-up, adjuvant pembro demonstrates improvement in OS in patients with ccRCC at risk of recurrence.
Advertisement
Knowledge Hub Spotlight
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Dr. Miles-Thomas shares the challenges of female urology and her vision for her tenure as AUA treasurer.
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Dr. Myers and colleagues challenge the current paradigm of discouraging additional BCG therapy for "unresponsive" NMIBC.
Advertisement
Advertisement
Latest News
Patients underwent treatment with lenvatinib plus everolimus as a second-line therapy.
An analysis of the phase 3 ARASENS study revealed new information on PSA responses and their association with outcomes.
A review analyzed 30 meta-analyses to determine the association between pretreatment NLR and immunotherapy outcomes.
